Goldridge Terminal ロゴ Goldridge Terminal
人気
ログイン

ウォッチリストに追加
Proチャート

Anteris Technologies Glob...

NasdaqGM: AVR · リアルタイム株価 · USD
8.87
-0.30 (-3.27%)
終値時点： Aug 12, 2026, 3:59 PM

Anteris Technologies Global Corp. (AVR) Stock Price, Analysis & Data

-3.27%
買気配5.95
時価総額864.46M
売上高（TTM）1.85M
純利益（TTM）-95.3M
ベータ0.73
EPS（TTM）-1.88
PER（TTM）n/a
予想PER-9.05
PBR（TTM）3.10
PSR（TTM）466.46
Earnings DateNov 12, 2026
売気配10.57
出来高817,451
平均出来高（20日）1,295,824
始値9.03
前日終値9.17
当日レンジ8.59 - 9.09
52週レンジ3.30 - 11.05
アナリストn/a
目標株価15 (69.11%)
配当n/a
権利落ち日n/a

AVRについて

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification prepa...

[続きを読む]
業種 Medical Instruments & Supplies
セクター Healthcare
IPO日 Dec 13, 2024
従業員数 174
上場取引所 NasdaqGM
ティッカー AVR
ウェブサイト https://anteristech.com
企業情報の全文

業績

2023年のAnteris Globalの売上高は2.73Mで、前年の3.2Mから-14.56%の減少でした。 利益は-46.02Mで、50.58%の増加でした。

財務諸表

アナリスト予想

3件のアナリスト評価によると、AVR株の平均レーティングは「null」です。12か月後の目標株価は15で、直近株価から69.11%の上昇余地となります。

株価予想

決算サプライズ

Anteris GlobalはAug 11, 2026に四半期決算を発表しました：
  • 売上高は n/a で、予想を下回りました $0, うち NaN% の前年比増加にあたります.
  • EPSは -0.3 で、予想を下回りました -0.09, うち 50.82% の前年比増加にあたります.

    • 次回決算発表

    Anteris Technologies Global Corp.の決算発表予定日は Nov 12, 2026, 取引時間中の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    1日前 · Proactive

    Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

    Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) made progress on its pivotal PARADIGM Trial during the June quarter, enrolling and treating its first US patients after securing Medicare reimburseme...

    news image

    2か月前 · Proactive

    France clearance marks key milestone for Anteris' pivotal PARADIGM Trial

    Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured full regulatory clearance from France's National Agency for Medicines and Health Products Safety (ANSM) for its global pivotal PARADIGM T...

    news image

    3か月前 · Simply Wall St.

    Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

    news image

    3か月前 · Proactive

    Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy

    Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has strengthened its board with the appointments of experienced healthcare and finance executive Susan Knight and company veteran Stephen Denaro as d...

    news image

    3か月前 · Proactive

    Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push

    Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has reported strong operational progress for the March 2026 quarter as the company advanced recruitment for its global PARADIGM pivotal trial and str...

    2ページ中1ページ